AimaLabs

Our mission is to revolutionize blood diagnostics, ensuring no disease goes undetected due to limited access to expert analysis. AimaLabs identifies peripheral blood cells with AI in a world where 5 billion complete blood counts are performed annually. With 84% of these tests lacking blood smear evaluation - a critical microscopic examination for cell morphology - countless cases of anemia, leukemia, and other disorders go undiagnosed or are detected too late.

Our AI-powered solution transforms peripheral blood cell analysis. Led by Dr. Vlacha, a pediatric hematologist and founder/CEO, we've developed software that automates manual microscopic examination. Blood smear images are fed into our algorithms, which instantly identify and count different normal and abnormal cell types with 97-98% accuracy.

In a market projected to reach $125 billion by 2033, our software-based approach makes expert-level analysis accessible anywhere - from major hospitals to remote clinics, medical laboratories, pharmaceutical companies, and research institutions. By converting a 10-20 minute manual process into instant, cost-effective automated analysis, we're democratizing access to vital diagnostic expertise and improving patient outcomes worldwide.